Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Drugs Laggard
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
(
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.4%. By the end of trading, Alexion Pharmaceuticals fell $1.31 (-1.2%) to $105.46 on light volume. Throughout the day, 927,003 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1,612,300 shares. The stock ranged in price between $104.84-$107.00 after having opened the day at $107.00 as compared to the previous trading day's close of $106.77. Other companies within the Drugs industry that declined today were:
(
), down 42.7%,
(
), down 28.8%,
(
TheStreet Recommends
), down 10.4% and
(
), down 9.1%.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $20.6 billion and is part of the health care sector. Shares are up 12.4% year to date as of the close of trading on Thursday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.
TheStreet Ratings rates
Alexion Pharmaceuticals
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.
- You can view the full Alexion Pharmaceuticals Ratings Report.
On the positive front,
(
), up 17.9%,
(
), up 17.5%,
(
), up 15.7% and
(
), up 13.6% , were all gainers within the drugs industry with
(
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null
